Nintedanib Combination Delayed Progression in Malignant Mesothelioma
Adding nintedanib to pemetrexed/cisplatin improved the progression-free survival of patients with malignant pleural mesothelioma compared with placebo.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Leah Lawrence Tags: Lung Cancer News Source Type: news
More News: Alimta | Asbestosis | Cancer | Cancer & Oncology | Legislation | Lung Cancer | Mesothelioma